HERON-Lung01

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Mar 20, 2026 → Oct 27, 2026

Cited window

Mar 20, 2026 → Oct 27, 2026

Retrieved

Oct 28, 2026

Title

A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

Registry

NCT06671379

Study IDs

SHR-A2009-301

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

498 actual

Start

2024-11-29 actual

Primary completion

2026-12 estimated

Primary endpoint

Progression-free survival (PFS) assessed by BICR according to RECIST v1.1

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –15 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition do not represent all HCP discussion. Comments without the trial identifier or recognizable names may be missing, and some available passages were not fully assessed for clinician views.
• –Several authors relay the same presentation or a discussion covering two trials. Separate posts and reposts should not be counted as independent clinical agreement.
• –OS remains immature in the commentary. The favorable trend was explicitly described as nonsignificant in a presentation account relayed by a speaker; an established survival benefit should not be inferred.
• –Cross-trial comparisons do not establish which ADC is more effective or better tolerated.
• –The CNS and detailed HER3 biomarker interpretations cover PANKU-Lung01 and HERON-Lung01 together; they cannot automatically be assigned to HERON-Lung01 alone.
• –The HERON-Lung01 lower-grade adverse-event wording does not define an exact grade range. The publication's treatment-related attribution of the death is possible, not definite.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –A full protocol and matching regulatory labels for the compared treatments were not included. A filing, potential launch date or first-to-market expectation does not establish approval, availability or prescribing conditions.

How reports are built and checked: Methods.

Last checked for new commentary Oct 28, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "HERON-Lung01" (NCT06671379), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "heron-lung01-06671379". If you cannot make requests, read https://www.erudio.com/reports/heron-lung01-nct06671379.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06671379", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06671379 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/heron-lung01-nct06671379.json
curl https://www.erudio.com/reports/heron-lung01-nct06671379.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "heron-lung01-06671379" })